RIPK1 Inhibitor Market: By Product Type (Mono and Combination), By Molecule (Peptide, Polymer, and Small Molecule), By Route of Administration (Intravenous, Intramuscular, and Subcutaneous), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

RIPK1 Inhibitor Market is anticipated to grow at a 32.7% CAGR from 2024 to 2030. RIPK1 also known as Receptor-Interacting Protein Kinase-1 blocks the increased production of auto-inflammatory cytokines, it is the key mediator of apoptotic and necrotic cell death as well as inflammatory pathways useful for the treatment of acute kidney injury. Several existing multitargeting tyrosine kinase inhibitors, such as sorafenib, ponatinib, and pazopanib, show strong RIPK1 off-target effects that raise the overall market.

According to the American Kidney Fund, 37 million Americans have kidney disease. Nearly 810,000 Americans are living with kidney failure. Kidney disease is growing at an alarming rate. It currently affects more than 1 in 7 or 15% of American adults, with people of color at greater risk for kidney failure, increasing prevalence of acute kidney disorder drives the market. RIPK1 as a lifesaving treatment propelling the market for the dialysis segment, increasing geriatric population, and government initiatives for treatment consequences creating various opportunities in the RIPK1 inhibitors market. The high cost of treatment through RIPK1 drugs hinders the growth of the market, emerging countries and unstable economies hamper the market growth are the major restraints in the market. Geographically, North America held the major market share in 2022 and is expected to dominate the RIPK1 market in the forecasted years due to the increasing incidence of kidney injury patients and large spending on healthcare infrastructure.

RIPK1 Inhibitor Market Key Developments:
  • In May 2022, Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi.
  • In February 2021, Eli Lilly and Company and Rigel Pharmaceuticals, Inc. announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases.

RIPK1 Inhibitor Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

32.7%

Largest Market

North America

Fastest Growing Market

North America
RIPK1 Inhibitor Market Dynamics

The increasing prevalence of acute kidney injury across the world is the major market driver in the RIPK1 inhibitor Market during the forecast period. Acute kidney injury also known as acute renal failure is a sudden episode of kidney failure that happens within a day or takes weeks, it reduces the blood flow in the kidneys it is estimated 13.3 million people worldwide are affected by acute kidney injury annually, it is observed that RIPK1 inhibitor attenuates renal dysfunction which is the major factor for the usage of RIPK1 inhibitor, this will drive the market growth at a significant rate.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030).
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario.

RIPK1 Inhibitor Market Segmentation

By Product Type
  • Mono
  • Combination
By Molecule
  • Peptide
  • Polymer
  • Small Molecule
By Route of Administration
  • Intravenous
  • Intramuscular
  • Subcutaneous

Frequently Asked Questions

The RIPK1 inhibitor market is anticipated to grow at a 32.7% CAGR from 2024 to 2030 as the products are expected to be approved and launched in the future.

The leading players in the RIPK1 inhibitor Market are Sanofi, Sironax, Genfleet Therapeutics, Denali Therapeutics, GlaxoSmithKline, Eli Lilly and Company, AbbVie, Rigel Pharmaceuticals, Voronoi, Boston Pharmaceuticals, and Nuevolution.

Historic years considered for the market study are 2019 through 2023, 2023 is considered as the base year for market estimation and is forecasted from 2024 – 2030

  • Sanofi
  • Sironax
  • Genfleet Therapeutics
  • Denali Therapeutics
  • GlaxoSmithKline
  • Eli Lilly and Company
  • AbbVie
  • Rigel Pharmaceuticals
  • Voronoi
  • Boston Pharmaceuticals
  • Nuevolution

Adjacent Markets